Skip to Content
Merck
All Photos(1)

Documents

C0450000

Carbamazepine

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

5H-Dibenz[b,f]azepine-5-carboxamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H12N2O
CAS Number:
298-46-4
Molecular Weight:
236.27
MDL number:
MFCD00005073
UNSPSC Code:
41116107
PubChem Substance ID:
329774792
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

carbamazepine

manufacturer/tradename

EDQM

mp

191-192 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC(=O)N1c2ccccc2C=Cc3ccccc13

InChI

1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

InChI key

FFGPTBGBLSHEPO-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Carbamazepine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Anticonvulsant; ligand for the GABAA receptor benzodiazepine modulatory site. Sodium channel inhibitor.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1093001

Carbamazepine, United States Pharmacopeia (USP) Reference Standard

Y0000033

Carbamazepine impurity A, European Pharmacopoeia (EP) Reference Standard

PHR1197

Iminostilbene, Pharmaceutical Secondary Standard; Certified Reference Material

1093023

Carbamazepine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1093012

Carbamazepine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1424084

9-Methylacridine, United States Pharmacopeia (USP) Reference Standard

BP974

Carbamazepine, British Pharmacopoeia (BP) Reference Standard

PHR1918

Carbamazepine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2433

Carbamazepine Impurity F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2330

Carbamazepine Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2237

Carbamazepine Impurity B, pharmaceutical secondary standard, certified reference material

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1A - Resp. Sens. 1 - Skin Sens. 1A - STOT SE 3

Target Organs

Central nervous system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

V L Yip et al.
Clinical pharmacology and therapeutics, 92(6), 757-765 (2012-11-08)
Carbamazepine (CBZ) therapy is associated with cutaneous adverse reactions in up to 10% of patients. Predisposition to these hypersensitivity reactions has been linked to the human leukocyte antigen (HLA) genotype. This systematic review determines the strength of these associations and
Janneke Jentink et al.
BMJ (Clinical research ed.), 341, c6581-c6581 (2010-12-04)
To identify specific major congenital malformations associated with use of carbamazepine in the first trimester of pregnancy. A review of all published cohort studies to identify key indications and a population based case-control study to test these indications. Review of
Ursula Amstutz et al.
Epilepsia, 55(4), 496-506 (2014-03-07)
To systematically review evidence on genetic risk factors for carbamazepine (CBZ)-induced hypersensitivity reactions (HSRs) and provide practice recommendations addressing the key questions: (1) Should genetic testing for HLA-B*15:02 and HLA-A*31:01 be performed in patients with an indication for CBZ therapy
Wimonchat Tangamornsuksan et al.
JAMA dermatology, 149(9), 1025-1032 (2013-07-26)
The US Food and Drug Administration recommends screening for the HLA-B*1502 allele before initiation of carbamazepine therapy in patients of Asian ancestry, but there remains unclear evidence of a relationship between HLA-B*1502 and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis
Philip J Wiffen et al.
The Cochrane database of systematic reviews, (1)(1), CD005451-CD005451 (2011-01-21)
Carbamazepine is used to treat chronic neuropathic pain. Evaluation of analgesic efficacy and adverse effects of carbamazepine for acute and chronic pain management (except headaches). Randomised controlled trials (RCTs) of carbamazepine in acute, chronic or cancer pain were identified, searching
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service